Wang Xiao-Yan, Deng Hong-Wei, Yang Jian, Zhu Xue-Mei, Xiang Feng-Ling, Tu Jing, Huang Ming-Xue, Wang Yun, Gan Jin-Hua, Yang Wei-Hua
School of Nursing, Southwest Medical University, Luzhou 646600, Sichuan Province, China.
Shenzhen Eye Institute, Shenzhen Eye Hospital, Jinan University, Shenzhen 518040, Guangdong Province, China.
Int J Ophthalmol. 2024 Jun 18;17(6):1128-1137. doi: 10.18240/ijo.2024.06.19. eCollection 2024.
To figure out whether various atropine dosages may slow the progression of myopia in Chinese kids and teenagers and to determine the optimal atropine concentration for effectively slowing the progression of myopia.
A systematic search was conducted across the Cochrane Library, PubMed, Web of Science, EMBASE, CNKI, CBM, VIP, and Wanfang database, encompassing literature on slowing progression of myopia with varying atropine concentrations from database inception to January 17, 2024. Data extraction and quality assessment were performed, and a network Meta-analysis was executed using Stata version 14.0 Software. Results were visually represented through graphs.
Fourteen papers comprising 2475 cases were included; five different concentrations of atropine solution were used. The network Meta-analysis, along with the surface under the cumulative ranking curve (SUCRA), showed that 1% atropine (100%)>0.05% atropine (74.9%) >0.025% atropine (51.6%)>0.02% atropine (47.9%)>0.01% atropine (25.6%)>control in refraction change and 1% atropine (98.7%)>0.05% atropine (70.4%)>0.02% atropine (61.4%)>0.025% atropine (42%)>0.01% atropine (27.4%)>control in axial length (AL) change.
In Chinese children and teenagers, the five various concentrations of atropine can reduce the progression of myopia. Although the network Meta-analysis showed that 1% atropine is the best one for controlling refraction and AL change, there is a high incidence of adverse effects with the use of 1% atropine. Therefore, we suggest that 0.05% atropine is optimal for Chinese children to slow myopia progression.
探讨不同剂量阿托品是否能减缓中国儿童和青少年近视的进展,并确定有效减缓近视进展的最佳阿托品浓度。
系统检索考克兰图书馆、PubMed、Web of Science、EMBASE、中国知网、中国生物医学文献数据库、维普数据库和万方数据库,纳入从建库至2024年1月17日期间关于不同浓度阿托品减缓近视进展的文献。进行数据提取和质量评估,并使用Stata 14.0软件进行网状Meta分析。结果以图表形式直观呈现。
纳入14篇文献,共2475例病例;使用了五种不同浓度的阿托品溶液。网状Meta分析及累积排序曲线下面积(SUCRA)显示,在屈光度变化方面,1%阿托品(100%)>0.05%阿托品(74.9%)>0.025%阿托品(51.6%)>0.02%阿托品(47.9%)>0.01%阿托品(25.6%)>对照组;在眼轴长度(AL)变化方面,1%阿托品(98.7%)>0.05%阿托品(70.4%)>0.02%阿托品(61.4%)>0.025%阿托品(42%)>0.01%阿托品(27.4%)>对照组。
在中国儿童和青少年中,五种不同浓度的阿托品均可减缓近视进展。虽然网状Meta分析显示1%阿托品在控制屈光度和眼轴长度变化方面效果最佳,但使用1%阿托品时不良反应发生率较高。因此,我们建议0.05%阿托品是减缓中国儿童近视进展的最佳选择。